Skip to Main Content

Paper Details

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.
Journal of Cancer Research and Clinical Oncology
5
2023
ARTEMIS, AbTCR, AbTCR construct, B, B-cell lymphoma, CAR, CD19, CD19-positive relapsed/refractory B-cell lymphoma, CRS, ET019003, ET019003 T cells, ICANS, T cells, T-cell, T-cell receptor, TCR, antibody, autologous CD19-directed AbTCR T cells, cancer, chimeric antigen receptor, cytokine release syndrome, gamma, gamma/delta, immune effector cell-associated neurotoxicity syndrome, patient, patients, tumor
Author NameAffiliation
Stephan A GruppPerelman School of Medicine, University of Pennsylvania
Stephan A GruppCenter for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia
  • 1 - 2

Datasets

Release 1.2